Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1

More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) — for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhongyu, Prabakaran, Ponraj, Chen, Weizao, Broder, Christopher C., Gong, Rui, Dimitrov, Dimiter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SP Wuhan Institute of Virology, CAS 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090799/
https://www.ncbi.nlm.nih.gov/pubmed/23575729
http://dx.doi.org/10.1007/s12250-013-3313-x
_version_ 1783509958670680064
author Zhu, Zhongyu
Prabakaran, Ponraj
Chen, Weizao
Broder, Christopher C.
Gong, Rui
Dimitrov, Dimiter S.
author_facet Zhu, Zhongyu
Prabakaran, Ponraj
Chen, Weizao
Broder, Christopher C.
Gong, Rui
Dimitrov, Dimiter S.
author_sort Zhu, Zhongyu
collection PubMed
description More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) — for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.
format Online
Article
Text
id pubmed-7090799
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher SP Wuhan Institute of Virology, CAS
record_format MEDLINE/PubMed
spelling pubmed-70907992020-03-24 Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1 Zhu, Zhongyu Prabakaran, Ponraj Chen, Weizao Broder, Christopher C. Gong, Rui Dimitrov, Dimiter S. Virol Sin Review More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) — for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics. SP Wuhan Institute of Virology, CAS 2013-04-11 /pmc/articles/PMC7090799/ /pubmed/23575729 http://dx.doi.org/10.1007/s12250-013-3313-x Text en © Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2013
spellingShingle Review
Zhu, Zhongyu
Prabakaran, Ponraj
Chen, Weizao
Broder, Christopher C.
Gong, Rui
Dimitrov, Dimiter S.
Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1
title Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1
title_full Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1
title_fullStr Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1
title_full_unstemmed Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1
title_short Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1
title_sort human monoclonal antibodies as candidate therapeutics against emerging viruses and hiv-1
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090799/
https://www.ncbi.nlm.nih.gov/pubmed/23575729
http://dx.doi.org/10.1007/s12250-013-3313-x
work_keys_str_mv AT zhuzhongyu humanmonoclonalantibodiesascandidatetherapeuticsagainstemergingvirusesandhiv1
AT prabakaranponraj humanmonoclonalantibodiesascandidatetherapeuticsagainstemergingvirusesandhiv1
AT chenweizao humanmonoclonalantibodiesascandidatetherapeuticsagainstemergingvirusesandhiv1
AT broderchristopherc humanmonoclonalantibodiesascandidatetherapeuticsagainstemergingvirusesandhiv1
AT gongrui humanmonoclonalantibodiesascandidatetherapeuticsagainstemergingvirusesandhiv1
AT dimitrovdimiters humanmonoclonalantibodiesascandidatetherapeuticsagainstemergingvirusesandhiv1

Ejemplares similares